ClinicalTrials.gg
RecruitingNCT05629546Updated Nov 18, 2026

Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors

A Phase 1 interventional study of Cytokine-induced memory-like natural killer cells and Relatilmab in Advanced Melanoma and Metastatic Melanoma, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Washington University School of Medicine · Phase 1, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Nov 18, 2026Now RecruitingEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Melanoma by Washington University School of Medicine — 3 open to participants now, 3 under way, none of them phase 3. Melanoma · Washington University School of Medicine.

Started
2024
the only one that year
Phase 1
5 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Melanoma by Washington University School of Medicine, this one is the only one that started in 2024, is one of 5 in phase 1, and was the 12th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 13 studies in Melanoma by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Melanoma by Washington University School of Medicine, or all of them as a file.
02

Study summary

This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test the variables of ML NK cell source. ML NK cells from an autologous source will be used for Arm 1, and ML NK cells from an allogeneic source will be used for Arm 2. The investigators hypothesize that ML NK cells from either an autologous source or allogeneic source are safe and tolerable in subjects with advanced and/or metastatic melanoma.

03

Conditions studied

  • Advanced Melanoma
  • Metastatic Melanoma

Browse trials for

Keywords

  • advanced melanoma
  • metastatic melanoma
  • checkpoint inhibitor resistant melanoma
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of confirmed advanced or melanoma that has progressed after at least 12 weeks or a minimum of 2 doses of treatment with a standard of care PD1/PDL1 containing therapy (nivolumab, pembrolizumab, atezolizumab, or durvalumab).
  • For Arm 1 ONLY: Patients must meet the eligibility criteria to undergo apheresis to obtain autologous NK cells as outlined below:

    • Patient must be willing and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
    • Patient must be negative for hepatitis, HTLV, and on the viral screen.
    • Patient may not be treated with any cytotoxic treatment within 2 weeks prior to leukapheresis.
  • For Arm 2 ONLY: Patient must have an available allogeneic NK cell donor who meets the eligibility criteria in the protocol.
  • Age: ≥18 years of age
  • Performance Status (ECOG) ≤ 2 at screening
  • Adequate organ function as defined below:

    • Total \< 2 mg/dL
    • (SGOT)/ALT(SGPT) \< 3.0 x
    • Creatinine within normal institutional limits OR > 40 mL/min/1.73 m\^2 by Cockcroft-Gault Formula
    • Oxygen saturation ≥ 90% on room air
    • ≥ 45%
  • Patients with a prior history of symptomatic must have received treatment and be neurologically stable for at least for 4 weeks and off anti-seizure medication and for 7 days prior to initiation of LDC.
  • Able to be off corticosteroids and any other immune suppressive medications for at least 14 days prior to apheresis or lymphodepletion and continuing until 30 days after the infusion of the ML NK cells. However, use of physiological dosing of corticosteroids (defined as ≤15mg prednisone or equivalent) is permitted if deemed medically necessary.
  • Women of must have a negative pregnancy test within 28 days prior to study registration. Female and male patients (along with their female partners) must agree to use two forms of acceptable , including one barrier method, throughout participation in the study and for at least 5 months after the last dose of relatlimab.
  • >12 weeks
  • Ability to understand and willingness to sign an IRB approved written document

Exclusion criteria

Exclusion Criteria:

  • Active disorder requiring (physiologic defined as ≤15mg prednisone or equivalent are acceptable).
  • Prior history of an immune-related Grade 3 or 4 AE attributed to prior cancer immunotherapy (other than endocrinopathy managed with either replacement therapy or asymptomatic elevation of serum amylase or lipase) that resulted in permanent discontinuation of the prior immunotherapeutic agent.
  • Patients with Grade ≤2 irAE who have not completely recovered from irAE (i.e. have residual toxicities >Grade 1) related to prior cancer immunotherapy (other than endocrinopathy management with replacement therapy or stable vitiligo). Patients treated with corticosteroids for irAE must demonstrate absence of related signs or symptoms for ≥7 days following discontinuation of corticosteroids.
  • , carcinomatous meningitis, or .
  • Known to one or more of the study agents.
  • Comorbidities and any conditions, that in the opinion of the investigator, that put the subject at unacceptable risk for study therapy or prevent the participant from consenting or participating in the study.
  • Uncontrolled and active systemic infections, including but not limited to , or C infection.
  • Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or suggestive of acute ischemia or active conduction system abnormalities.
  • New progressive pulmonary infiltrates concerning for new or uncontrolled infectious process. Infiltrates attributed to infection must be stable/ improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections).
  • Received any or off-label drugs, or cytotoxic chemotherapy within the 14 days or five half-lives (whichever is greater) prior to apheresis.
  • Pregnant or breastfeeding.
  • Subjects are not acceptable candidates if they received prior tumor infiltrating lymphocytes (TIL) therapy (either in the setting of clinical trial or standard of care if TIL therapy is FDA approved in the future), or an organ allograft.
  • Has a known additional that is progressing or required active treatment within the past 2 years. Note: participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg. Breast carcinoma, cervical cancer in situ) that has undergone potentially curative therapy are not excluded.
  • Received a live or attenuated vaccine within 28 days prior to the beginning of the lymphodepletion therapy.

Eligibility Criteria for Haploidentical Donors (For Arm 2 only)

  • Donor must be at least 18 years of age.
  • Donor must be willing, in general good health, and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
  • Donor must be negative for hepatitis, HTLV, and HIV on donor viral screen.
  • Donor may not be pregnant and/or breastfeeding. Women of must have a negative pregnancy test within 30 days prior to apheresis.
  • Donor must be able to understand and willing to sign an IRB-approved written document.
  • Only haploidentical donors will be included.
  • Donor must meet the requirements of institutional donor guidelines, including the requirements of Foundation for the Accreditation of Hematopoietic Cell Therapy (FACT) criteria.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Arm 1: Autologous: Memory-like natural killer cells + nivolumab + relatilimab

    * Subjects enrolled into arm 1 will receive autologous ML NK cells on Day 0. * Relatlimab and nivolumab will be initiated at day 29 and continue every 28 days for 11 cycles, or until unacceptable toxicity, or progression, whichever is earlier.

    Biological: Cytokine-induced memory-like natural killer cells · Biological: Relatilmab · Biological: Nivolumab

  • Experimental
    Arm 2: Allogeneic: Memory-like natural killer cells + nivolumab + relatilimab

    * Subjects with a haploidentical donor will enroll into Arm 2 * Subjects will receive the IV infusion of ML NK cells on Day 0. * Relatlimab and nivolumab will be initiated at day 29 and continue every 28 days for 11 cycles, or until unacceptable toxicity, or progression, whichever is earlier.

  • No intervention
    Allogeneic Donors

Interventions

  • BiologicalCytokine-induced memory-like natural killer cells

    Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).

    Also known as: ML NK cells, CIML

  • BiologicalRelatilmab

    Standard of care

    Also known as: Opdualag

  • BiologicalNivolumab

    Standard of care

06

What researchers measure

Primary outcomes

  1. For treatment with cells from an autologous source: Incidence and severity of adverse events

    -As determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

    Time frame: From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)

  2. For treatment with cells from an allogeneic source: Incidence and severity of adverse events

    -As determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)

    Time frame: From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)

Secondary outcomes

  1. Objective response rate (ORR)

    Objective response rate (ORR), defined as the proportion of patients with a complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, according to RECIST v1.1. 4 weeks apart. * Complete Response (CR). Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm).Disappearance of all non-target lesions and normalization of tumor marker level. * Partial Response (PR). At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Through completion of treatment (estimated to be 12 months)

  2. Duration of response (DOR)

    -Duration of response (DoR), defined as the time from the first occurrence of a documented response after the ML NK cell infusion, to disease progression according to RECIST v1.1 or death.

    Time frame: Through completion of follow-up (estimated to be 3 years)

  3. Progression-free survival (PFS)

    * PFS, defined as the time from ML NK cell infusion to the first occurrence of disease progression according to RECIST 1.1 or death from any cause. * Progressive Disease (PD). At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm (0.5 cm). Appearance of 1 or more new lesions and/or unequivocal progression of existing non-target lesions. Unequivocal progression should not normally trump target lesion status. It must be representative of overall disease status change, not a single lesion increase.

    Time frame: Through completion of follow-up (estimated to be 3 years)

  4. Disease control rate (DCR)

    * Disease control rate (DCR), defined as the percentage of patients who have achieved a complete response, partial response, or stable disease according to RECIST v1.1. * Complete Response (CR). Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm (\<1 cm).Disappearance of all non-target lesions and normalization of tumor marker level. * Partial Response (PR). At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. * Stable Disease (SD). Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

    Time frame: Through completion of follow-up (estimated to be 3 years)

  5. Overall survival (OS)

    -OS, defined as the time from ML NK cell infusion to death from any cause.

    Time frame: Through completion of follow-up (estimated to be 3 years)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Alice Y Zhou, M.D., Ph.D. · Contactalice.y.zhou@wustl.edu · 314-362-5677
    • Alice Y Zhou, M.D., Ph.D. · Principal investigator
    • Todd A Fehniger, M.D., Ph.D. · Sub investigator
    • Tanner M Johanns, M.D., Ph.D. · Sub investigator
    • George Ansstas, M.D. · Sub investigator
    • Charles Kaufman, M.D., Ph.D. · Sub investigator
    • Ryan Fields, M.D. · Sub investigator
    • Armin Ghobadi, M.D. · Sub investigator
    • Amanda Cashen, M.D. · Sub investigator
    • Feng Gao, M.D., Ph.D., MPH, MS · Sub investigator
    • Jesse Keller, M.D. · Sub investigator
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Feb 2029, 51 months after the start.

Of 186 non-industry phase 1 interventional studies under Melanoma, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 82. This study's planned 51 months is close to that.

Counting every sponsor, half of 412 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Nov 29, 2022
StartActual
Nov 6, 2024
Primary completionEst.
Feb 28, 2029
CompletionEst.
Nov 30, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Oct 23, 2026
Sites
Washington University School of Medicine is now Recruiting
Oct 23, 2026
Eligibility
2 inclusion criteria edited, 4 added; 1 exclusion criterion edited, 4 removed
What changed in the criteria
Inclusion criteria
  • EditedHave an Eastern Cooperative Oncology Group Performance Status (ECOG) ≤ 2 at screening FormFor Arm 1 onlyONLY: Patients must meet the eligibility criteria to undergo apheresis to obtain autlogousautologous NK cells. as outlined below:
  • AddedPatient must be willing and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
  • AddedPatient must be negative for hepatitis, HTLV, and HIV on the viral screen.
  • AddedPatient may not be treated with any cytotoxic treatment within 2 weeks prior to leukapheresis.
  • EditedFor Arm 2 onlyONLY: Patient must have an available allogeneic NK cell donor who meets the eligibility criteria in the protocol.
  • AddedEastern Cooperative Oncology Group Performance Status (ECOG) ≤ 2 at screening
Exclusion criteria
  • ChangedBefore Leptomeningeal disease, carcinomatous meningitis, or symptomatic CNS metastases. Patients with asymptomatic brain metastasis with no pending intervention needed, or patients with treated CNS disease and stable for at least 4 weeks and off anti-seizure medication and steroids for 7 days prior to initiation of LDC are eligible.Now Leptomeningeal disease, carcinomatous meningitis, or CNS metastases.
  • RemovedEligibility Criteria for Autologous Patients (For Arm 1 only)
  • RemovedPatient must be willing and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
  • RemovedPatient must be negative for hepatitis, HTLV, and HIV on the viral screen.
  • RemovedPatient may not be treated with any cytotoxic treatment within 2 weeks prior to leukapheresis.
Nov 18, 2026
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameFor treatment with cells from an autologous source: Incidence and severity of adverse eventsFrom start of treatment through end of safety follow-up (estimated to be 15 months) → From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)
  • Time frameFor treatment with cells from an allogeneic source: Incidence and severity of adverse eventsFrom start of treatment through end of safety follow-up (estimated to be 15 months) → From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)
Nov 18, 2026
Contact
Study contact now listed: added a•••@wustl.edu · •••5677. See the current contact
Oct 23, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Washington University School of Medicine · St Louis, United StatesContact added a•••@wustl.edu · •••5677Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
Oct 23, 2026
Show all 2 updates
  1. Nov 18, 2026
    Eligibility 2 inclusion criteria edited, 4 added; 1 exclusion criterion edited, 4 removed
    What changed in the criteria
    Inclusion criteria
    • EditedHave an Eastern Cooperative Oncology Group Performance Status (ECOG) ≤ 2 at screening FormFor Arm 1 onlyONLY: Patients must meet the eligibility criteria to undergo apheresis to obtain autlogousautologous NK cells. as outlined below:
    • AddedPatient must be willing and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
    • AddedPatient must be negative for hepatitis, HTLV, and HIV on the viral screen.
    • AddedPatient may not be treated with any cytotoxic treatment within 2 weeks prior to leukapheresis.
    • EditedFor Arm 2 onlyONLY: Patient must have an available allogeneic NK cell donor who meets the eligibility criteria in the protocol.
    • AddedEastern Cooperative Oncology Group Performance Status (ECOG) ≤ 2 at screening
    Exclusion criteria
    • ChangedBefore Leptomeningeal disease, carcinomatous meningitis, or symptomatic CNS metastases. Patients with asymptomatic brain metastasis with no pending intervention needed, or patients with treated CNS disease and stable for at least 4 weeks and off anti-seizure medication and steroids for 7 days prior to initiation of LDC are eligible.Now Leptomeningeal disease, carcinomatous meningitis, or CNS metastases.
    • RemovedEligibility Criteria for Autologous Patients (For Arm 1 only)
    • RemovedPatient must be willing and medically able to tolerate leukapheresis required for harvesting the NK cells for this study.
    • RemovedPatient must be negative for hepatitis, HTLV, and HIV on the viral screen.
    • RemovedPatient may not be treated with any cytotoxic treatment within 2 weeks prior to leukapheresis.
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameFor treatment with cells from an autologous source: Incidence and severity of adverse eventsFrom start of treatment through end of safety follow-up (estimated to be 15 months) → From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)
    • Time frameFor treatment with cells from an allogeneic source: Incidence and severity of adverse eventsFrom start of treatment through end of safety follow-up (estimated to be 15 months) → From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)
    + 1 other change: verification date
  2. Oct 23, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    Washington University School of Medicine is now Recruiting
    Contact Study contact now listed: added a•••@wustl.edu · •••5677. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Washington University School of Medicine · St Louis, United StatesContact added a•••@wustl.edu · •••5677Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05629546
Collaborators
Melanoma Research Alliance, Rising Tide Foundation
Responsible party
Sponsor
First posted
Nov 29, 2022
Start date
Nov 6, 2024
Primary completion
Feb 28, 2029 (estimated)
Completion
Nov 30, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Alice Y Zhou, M.D., Ph.D.
Contact
alice.y.zhou@wustl.edu
314-362-5677
Alice Y Zhou, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion